dunno on DNDN, CAB...but Adam Fueststein came up with a valuation model for Provenge...you might want to read this old article...fwiw <A HREF="http://www.thestreet.com/newsanalysis/pharmaceuticals/10345925.html" target="_blank">http://www.thestreet.com/newsanalysis/pharmaceuticals/10345925.html</A>